DNA replication is one of the fundamental biological processes in which dysregulation can cause genome instability. This instability is one of the hallmarks of cancer and confers genetic diversity during tumorigenesis. Numerous experimental and clinical studies have indicated that most tumors have experienced and overcome the stresses caused by the perturbation of DNA replication, which is also referred to as DNA replication stress (DRS). When we consider therapeutic approaches for tumors, it is important to exploit the differences in DRS between tumor and normal cells. In this review, we introduce the current understanding of DRS in tumors and discuss the underlying mechanism of cancer therapy from the aspect of DRS. Figure 1B) , inhibition of DNA polymerase activity (Figure 1C) , blockage of DNA unwinding by DNA cross-links or inhibition of topoisomerases ( Figure 1D ), or blockage of DNA polymerase progression by DNA adducts or strand breaks ( Figure 1E ). These obstacles cause the slowing or stalling of replication fork progression and DNA synthesis while also triggering DRS. 16 For these malignant tumors, chemotherapeutic drugs that induce further DRS are thought to be effective. 17 In this section, we introduce several key signal transduction pathways of the DDR, a result of DRS, which are regulated by ATM and ATR kinases ( Figure 3 ).
| ATR kinase is activated at stalled replication forks and phosphorylates hundreds of downstream substrates, including Chk1
Both ATM and ATR are phosphoinositide 3-kinase-related protein kinases that preferentially phosphorylate serine/threonine residues that are followed by glutamine (Ser/Thr-Gln) in various downstream target proteins that promote cell cycle arrest or DNA repair. 18 In particular, ATR is responsible for the DDR signal transduction pathway when DNA replication is perturbed. 19 ATR kinase is mainly activated in replication protein A-coated ssDNA regions by anchoring ATRIP. 19 Optimal ATR activation required the Rad9-Rad1-Hus1 sliding clamp, which forms a heterotrimeric ring structure and is loaded at the boundary of the ssDNA and dsDNA regions, 20 and DNA topoisomerase 2b-binding protein 1, which contains 8 BRCA1 A and Cyclin B, in a p53-dependent manner. 46 Intriguingly, oxaliplatin robustly activates p53 and leads to accumulation of p21 in spite of low levels of activation of ATM and ATR. 47 This finding may be consistent with a recent report indicating that oxaliplatin kills cells by inducing ribosome biogenesis stress, but not through the DDR pathway. 48 The p53 activation by oxaliplatin causes the transcriptional repression of deoxyuridine triphosphatase, which catalyzes the hydrolysis of dUTP to dUMP and inhibits dUTP-mediated cytotoxicity, 49 as well as the enzymes involved in thymidylate biosynthesis, such as dihydrofolate reductase, thymidine kinase 1, and thymidylate synthase, through miR-34a-mediated E2F1 and E2F3 downregulation. 47 These effects may elucidate the clinical synergy observed between oxaliplatin and 5-FU in FOLFOX, a combination regimen of 5-FU, leucovorin and oxaliplatin, which is superior in the treatment of advanced colorectal cancer patients 50 or for adjuvant therapy for colorectal cancer patients who received curable surgery. Topoisomerase is an enzyme that catalyzes the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. 52 There are 2 types of topoisomerases: Topo I, which cuts 1 of the 2 strands of dsDNA and relaxes/reanneals the strand, and Topo II, which cuts both strands of dsDNA simultaneously and manages DNA tangles. Topoisomerase inhibitors are chemical compounds that block the action of these topoisomerases and often work as a chemotherapeutic drug.
| CH EMOTH ERAPEUTIC DR UGS THAT INDUCE AND MODULATE DRS
CPT is a cytotoxic alkaloid that works as a Topo I inhibitor.
Irinotecan is a CPT analog that has been approved as a phase. This cytotoxicity is a result of the conversion of ssDNA breaks into 1-ended dsDNA breaks when the replication fork encounters and collides with Topo I-cc. 53 Distinct from the 2-ended dsDNA breaks formed by ionizing radiation, 1-ended dsDNA breaks are extremely cytotoxic, possibly because these breaks cannot be repaired by the non-homologous end-joining process. 54 The Topo Icc-mediated DNA ends induce both ATM and ATR activation and must be properly resected to expose the ssDNA region for repair by homologous recombination. Accordingly, CPT induces hyperphosphorylation of FANCJ, a DNA helicase that participates in DNA replication checkpoint control 55, 56 and contributes to suppress microsatellite instability, 57 in an end-resection and ATR-dependent manner. 58 Thus, this CPT-induced hyperphosphorylation of FANCJ may have certain roles in replication-coupled DNA repair processes, such as homologous recombination. Ser345 phosphorylation and the robust accumulation of p53 and p21, which were associated with Chk2 Thr68 phosphorylation. 61 FTD induced sustained arrest at the G 2 phase by downregulating cyclin B1/Cdk1 expression, 61 which is also observed when cellular senescence is induced. 63 Although the mechanism underlying the induction of DDR by FTD is currently unclear, FTD appears to exert its cytotoxicity in a unique fashion during replication.
| CONCLUSION
DNA replication is an essential process for cell proliferation; at the same time, it is a fragile system and susceptible to the effects of intrinsic or exogenous environmental factors. Here, we described the underlying mechanism by which DRS is induced at the early stages of cancer development, triggers genome instability, and promotes tumor progression. As induction of DRS appears to be a common event during tumorigenesis, most malignant tumor cells are thought to survive in the presence of severe DRS. Exploiting DRS is a prospective strategy for cancer therapy. 17 To develop novel cancer therapeutic regimens that maximize antitumor effects and minimize adverse effects on normal tissues, it will be important to: (i) comprehend the extent of DRS in tumors; (ii) uncover the underlying molecular mechanism of DRS elicited by each drug; and (iii) find optimal ways of modulating or combining chemotherapeutic drugs that enhance cytotoxicity exclusively in tumors.
Molecular targeting drugs that modulate DDR in response to DRS are expected to have antitumor effects. Indeed, several kinase inhibitors against ATR or Chk1 are currently under investigation in clinical trials as anticancer drugs. 64 We anticipate that even low doses of these drugs would significantly enhance the anticancer effect of chemotherapeutic drugs that trigger DRS. In addition, genomic instability or hypermutability induced by DRS caused by an intrinsic trait (eg, mismatch-repair deficiency) or by a chemotherapeutic drug, may enhance tumor susceptibility to therapies like immunocheckpoint blockers. 65 Further understanding of DRS in tumors as well as development of novel therapeutic options will pave the way to proceed into the next generation of cancer therapy.
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